Athersys cuts its losses slightly in third quarter | Crain's Cleveland Business
The Cleveland-based regenerative medicine company said a restructuring launched in the summer is 'largely completed' and is helping to control costs. Cash, though, remains a challenge, and Athersys said it will 'continue to seek strategic partnership opportunities to advance our MultiStem platform and provide non-dilutive funding.'